This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Howell, B. A. Articles by Chauhan, A. PubMed Articles by Howell, B. A. Articles by Chauhan, A. Related Collections Drug Delivery Patient Safety Regional Anesthesia Pharmacology

---

ANALGESIA

Bupivacaine Binding to Pegylated Liposomes

From the Department of Chemical Engineering, University of Florida, Gainesville, Florida.

Address correspondence and reprint requests to Dr. Anuj Chauhan, Department of Chemical Engineering, University of Florida, Gainesville, FL 32611. Address e-mail to chauhan{at}che.ufl.edu.

Abstract

BACKGROUND: Local anesthetic drugs, such as bupivacaine, can cause severe toxicity. Lipid emulsions have been proposed and used clinically for treating such cases. Liposomes may be an alternative for overdose treatment because of their unique structures and surface charges, which allows them to act as high affinity drug "sinks" and remove bupivacaine from solution.

METHODS: We conducted in vitro experiments with unilamellar and multilamellar anionic, polymer-coated liposomes to determine the amount of bupivacaine bound to liposomes in buffer solutions as a means of assessing the liposome-drug affinity. Binding experiments were also done in human serum to determine the liposomes’ ability to compete with serum proteins for binding drug molecules.

RESULTS: Unilamellar liposomes sequestered 60%–65% and 77%–85% of bupivacaine from buffer at 1.45 and 2.9 mg lipid/mL, respectively. The increased lipid loading increased the drug uptake at all drug concentrations measured (P = 0.001, 0.002, <0.001, and 0.003 for 5, 20, 35, and 50 µM, respectively). Multilamellar liposomes bound more drug per unit mass, with 71%–90% of the total bupivacaine bound at a phospholipid concentration of 1.45 mg lipid/mL. When comparing unilamellar and multilamellar liposomes at 1.45 mg lipid/mL, the multilamellar liposomes were significantly better at 3 of the 4 drug concentrations measured (P = 0.002, 0.001, 0.001, and 0.08 for 5, 20, 35, and 50 µM, respectively). In human serum samples, unilamellar liposomes (2.9 mg lipid/mL) reduced the unbound (free) drug by 36% (P = 0.037), 56% (P = 0.022), 47% (P = 0.042), and 50% (P = 0.018) for bupivacaine concentrations of 5, 20, 35, and 50 µM, respectively.

CONCLUSIONS: The anionic, pegylated liposomes exhibit high binding for bupivacaine, both in buffer and in human serum. These results suggest that an IV injection of liposomes could be useful for the treatment of bupivacaine toxicity through drug redistribution.